Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease
| Autor: | Abdul, S., Boender, J., Malfliet, J.J.M.C., Eikenboom, J., Draat, K.F. van, Mauser-Bunschoten, E.P., Meijer, K., Meris, J. de, Laros-van Gorkom, B.A.P., Bom, J.G. van der, Leebeek, F.W.G., Rijken, D.C., Willige, S.U. de, Study Grp |
|---|---|
| Přispěvatelé: | Paediatric Infectious Diseases / Rheumatology / Immunology, Vascular Medicine, Amsterdam Cardiovascular Sciences, ACS - Pulmonary hypertension & thrombosis, Vascular Ageing Programme (VAP), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Hematology |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_treatment Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] PAI-1 030204 cardiovascular system & hematology Gastroenterology Cohort Studies chemistry.chemical_compound 0302 clinical medicine hemic and lymphatic diseases Medicine Child VWD Genetics (clinical) Aged 80 and over biology Hematology General Medicine Middle Aged Phenotype bleeding score von Willebrand Diseases Child Preschool Plasminogen activator inhibitor-1 Population study plasminogen activator inhibitor-1 Female fibrinolysis von Willebrand disease Adult medicine.medical_specialty Adolescent Genotype Hemorrhage DIAGNOSIS Young Adult 03 medical and health sciences Von Willebrand factor Internal medicine Plasminogen Activator Inhibitor 1 Fibrinolysis Von Willebrand disease Humans Aged business.industry Infant Plasma levels medicine.disease Surgery chemistry biology.protein MODERATE business Plasminogen activator 030215 immunology |
| Zdroj: | Haemophilia, 23(3), 437-443. Wiley-Blackwell Haemophilia, 23, 3, pp. 437-443 Haemophilia Haemophilia, 23, 437-443 Haemophilia, 23(3), 437-443. Wiley Haemophilia, 23(3), 437-443 Haemophilia, 23(3), 437-443. Wiley-Blackwell Publishing Ltd |
| ISSN: | 1351-8216 |
| Popis: | Item does not contain fulltext INTRODUCTION: von Willebrand disease (VWD) is the most common inherited bleeding disorder. In VWD patients, large variations in bleeding tendency are observed, which cannot be completely explained by the variation in von Willebrand factor levels or activities. Thus, there must be additional factors, for instance, changes in fibrinolysis that have an effect on the variation in bleeding tendency in VWD patients. AIM: To investigate whether plasminogen activator inhibitor-1 (PAI-1) level influences the variation in bleeding tendency in VWD patients. METHODS: PAI-1 antigen levels were measured in the plasma of 633 patients with moderate or severe VWD who participated in the 'Willebrand in the Netherlands' (WiN) study, a nationwide multicentre cross-sectional study. Bleeding severity was assessed using the Tosetto bleeding score. RESULTS: PAI-1 levels increased with age (Spearman's rho: 0.225, P < 0.001) and were higher in men (23 [IQR 12-60] vs. 20 [IQR 10-44] ng mL-1 in women, P = 0.039), whereas the bleeding score was higher in women (11 [IQR 7-17] vs. 9 [IQR 5-14] ng mL-1 in men, P = 0.002). After adjustment for age and sex by stratification, PAI-1 level and bleeding score were negatively correlated (Spearman's rho: -0.170, P = 0.017) in the group of 196 young (age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|